| Title |
|
|
|
Identification of a Wilms' tumor 1-derived immunogenic T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes
| |
| Author |
|
|
|
| |
| Abstract |
|
|
|
| The Wilms tumor 1 (WT1) protein is a tumor-associated antigen that is overexpressed in a wide range of solid and hematological malignancies.1 WT1 is also known to be frequently overexpressed in acute myeloid leukemia (AML) and is thus suitable for antigen-targeted immunotherapy of AML.2 Previous clinical trials, including both peptide and WT1-targeted dendritic cell (DC) vaccine approaches, have already provided tangible evidence of the clinical anti-leukemic activity of WT1-based immunotherapy in AML patients.1, 3, 4, 5, 6, 7 Several characteristics make WT1 an ideal immunotherapeutic target in AML, including its overexpression in bulk AML cells as well as in the leukemic stem cell compartment, its established role in leukemogenesis and its potent immunogenicity.2 The fact that WT1 is one of the few leukemia-associated antigens from which different CD4+ helper T-cell epitopes have been identified undoubtedly contributes to its superior immunogenicity profile,2 as CD4+ T-cell help is considered critical for the induction of effective anti-tumor immunity. | | |
| Language |
|
|
|
English
| |
| Source (journal) |
|
|
|
Leukemia. - Baltimore, Md, 1987, currens | |
| Publication |
|
|
|
Baltimore, Md : 2013
| |
| ISSN |
|
|
|
0887-6924 [print]
1476-5551 [online]
| |
| Volume/pages |
|
|
|
27:3(2013), p. 748-750
| |
| ISI |
|
|
|
000316587300037
| |
| Full text (Publisher's DOI) |
|
|
| | |
|